NCT07752407Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

Study sponsor: Phathom Pharmaceuticals, Inc. · PHAT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-10-20Estimated
Enrollment · participants500Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.